Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Total Non-current Liabilities
All obligations due after more than one year.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities remains negative
Q1 FY2026 total non-current liabilities was $0, compared with $360K a year earlier.
Context
- Total non-current liabilities amounted to 0.0% of total assets at the end of Q1 FY2026, down 0.2 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 127.22M | +189.4% |
| FY2023 | 2023-12-31 | 43.96M | -0.3% |
| FY2022 | 2022-12-31 | 44.09M | — |
Total Non-current Liabilities vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's Mar 2026 total non-current liabilities of $0 is the 10th highest of the 11 companies compared; the peer median is $18.23M.
- Its year-over-year change of -100.0% is the lowest of 9, against a peer median of -4.1%.
- Total non-current liabilities amounts to 0.0% of total assets for AARD, versus a peer median of 16.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $234.17M | -6.0% | -10.9% | 105.4% | |
| Mar 2026 | $151.67M | -17.3% | +78.5% | 48.2% | |
| Mar 2026 | $27.31M | -2.3% | -14.7% | 18.3% | |
| Mar 2026 | $25.02M | -0.3% | -2.6% | 14.1% | |
| Mar 2026 | $19.97M | +94.0% | -2.6% | 20.0% | |
| Mar 2026 | $16.5M | -10.0% | -3.5% | 25.7% | |
| Mar 2026 | $12.1M | +16.3% | -10.1% | 9.0% | |
| Mar 2026 | $1.9M | -92.5% | -10.1% | 0.8% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $1.81M | — | -81.5% | 1.2% |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
ZURAZura Bio Limited | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding AARD) | $18.23M | -4.1% | -10.1% | 16.2% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.